Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5497326 | 0.85 | OPRM1 (0.54) | DRD4GRM2EPHX1 | |
| SCHEMBL695325 | 0.79 | MEN1 (0.56) | DRD4CCR3 | |
| Hydrochloric Acid SCHEMBL2807810 | 0.78 | MEN1 (0.59) | DRD4CCR3 | |
| SCHEMBL5493941 | 0.78 | GRM2 (0.52) | GRM2SIGMAR1KDM4EEPHX1 | |
| SCHEMBL15760101 | 0.75 | HRH3 (0.59) | DRD4CCR3METAP2METAP1 | |
| Trifluoroacetic Acid SCHEMBL5040989 | 0.73 | DRD4 (0.48) | DRD4SIGMAR1CCR3FFAR1 | |
| SCHEMBL3644107 | 0.73 | OPRM1 (0.52) | DRD4 | |
| SCHEMBL375103 | 0.73 | DRD4 (0.46) | DRD4CCR3 | |
| SCHEMBL1007347 | 0.73 | SLC6A4 (0.56) | DRD4CCR3 | |
| Hydrochloric Acid SCHEMBL6186358 | 0.72 | SLC6A4 (0.55) | DRD4CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262163-B2 | Short amphipathic peptides with activity against bacteria and intracellular pathogens | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2007-08-28 | — | — | US | claimed |
| US-20040059088-A1 | Short amphipathic peptides with activity against bacteria and intracellular pathogens | MCLAUGHLIN MARK L (US) | 2004-03-25 | — | — | US | claimed |
| US-6566334-B1 | For therapy of bacterial infection | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2003-05-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040059088-A1 | Short amphipathic peptides with activity against bacteria and intracellular pathogens | VIP, MDK, HM13 | DRD4 1156/4885GRM2 4555/4885SIGMAR1 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.